Clinical features of insulin resistance and beta cell dysfunction and the relationship to type 2 diabetes

被引:2
|
作者
Stumvoll, M
Gerich, J
机构
[1] Univ Rochester, Sch Med, Endocrine Metab Unit, Rochester, NY 14642 USA
[2] Univ Rochester, Sch Med, Gen Clin Res Ctr, Rochester, NY 14642 USA
[3] Univ Tubingen, Med Clin, Dept Endocrinol Metab & Pathobiochem, Tubingen, Germany
关键词
D O I
暂无
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Type 2 diabetes mellitus is a heterogeneous disorder characterized by varying degrees of impaired insulin secretion and insulin resistance. The metabolic manifestations of insulin resistance include (1) reduced insulin-stimulated glucose uptake, (2) reduced insulin-suppression of endogenous glucose production, and (3) reduced antilipolysis. All of these mechanisms contribute to the hyperglycemia of T2DM, both post-absorptively and postprandially. In addition, insulin resistance is involved in decreased insulin-induced vasodilation, dyslipidemia, and platelet hyperaggregability. The pathogenesis of T2DM involves a combination of genetic and environmental factors. Monogenic causes account for only a minority of insulin resistance and beta cell dysfunction. Among environmental factors the most important are obesity, reduced physical activity, and age. Obesity-associated insulin resistance is thought to be mediated mainly by FFAs whose clearance is reduced in subjects with T2DM. A number of clinical tests have been developed to assess insulin sensitivity and beta cell function in vivo. The euglycemic hyperinsulinemic clamp and the hyperglycemic clamp, respectively, represent the gold standard procedures. Recently, indices calculated from parameters of the OGTT have been proposed as surrogates for assessing both insulin sensitivity and beta cell function in clinical situations and epidemiologic studies.
引用
收藏
页码:31 / +
页数:22
相关论文
共 50 条
  • [1] Frequency of insulin resistance and beta cell dysfunction and their relations with clinical and biochemical features in newly-diagnosed type 2 diabetes
    Bonora, E.
    Stoico, V.
    Negri, C.
    Trombetta, M.
    Tommasi, C.
    Grippaldi, F.
    Brangani, C.
    Pichiri, I.
    Tecilazich, F.
    Muggeo, A.
    Bonadonna, R. C.
    [J]. DIABETOLOGIA, 2008, 51 : S263 - S263
  • [2] Relationship Between Insulin Resistance and β-Cell Dysfunction in Subphenotypes of Prediabetes and Type 2 Diabetes
    Faerch, Kristine
    Johansen, Nanna B.
    Witte, Daniel R.
    Lauritzen, Torsten
    Jorgensen, Marit E.
    Vistisen, Dorte
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2015, 100 (02): : 707 - 716
  • [3] The evolution of β-cell dysfunction and insulin resistance in type 2 diabetes
    Bergman, RN
    Finegood, DT
    Kahn, SE
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2002, 32 : 35 - 45
  • [4] The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes
    S. E. Kahn
    [J]. Diabetologia, 2003, 46 : 3 - 19
  • [5] The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes
    Kahn, SE
    [J]. DIABETOLOGIA, 2003, 46 (01) : 3 - 19
  • [6] Soluble RAGE is unlikely to induce type 2 diabetes by inducing insulin resistance or beta cell dysfunction
    Biswas, S. K.
    Mohtarin, S.
    Mudi, S. R.
    Anwar, T.
    Alam, S. M. K.
    Arslan, M. I.
    [J]. DIABETOLOGIA, 2014, 57 : S246 - S247
  • [7] Ageing and type 2 diabetes in an elderly chinese population: the role of insulin resistance and beta cell dysfunction
    Liu, J.
    Wu, Y. -Y.
    Huang, X. -M.
    Yang, M.
    Zha, B. -B.
    Wang, F.
    Zha, Y.
    Sheng, L.
    Chen, Z. -P. G.
    Gu, Y.
    [J]. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2014, 18 (12) : 1790 - 1797
  • [8] Insulin resistance versus β-cell dysfunction in the pathogenesis of type 2 diabetes
    Ferrannini, Ele
    [J]. CURRENT DIABETES REPORTS, 2009, 9 (03) : 188 - 189
  • [9] Insulin resistance versus β-cell dysfunction in the pathogenesis of type 2 diabetes
    Ele Ferrannini
    [J]. Current Diabetes Reports, 2009, 9 : 188 - 189
  • [10] Insulin resistance and β-cell dysfunction as therapeutic targets in type 2 diabetes
    Evans, AJ
    Krentz, AJ
    [J]. DIABETES OBESITY & METABOLISM, 2001, 3 (04): : 219 - 229